A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is designed to determine the influence of food on the absorption and relative bioavailability of oral ganciclovir by comparing the absorption of oral ganciclovir in a fed and fasting state at steady state plasma levels.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
13 Years to 60 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have the following:
Confirmation of HIV infection by HIV antibody testing, p24 antigen, or culture of HIV.
Documented confirmation of present or past CMV infection.
Must understand the nature of the study, agree to tests required in the protocol, and must understand and sign an informed Consent form approved by the appropriate Institutional Review Board and by Syntex.
Patients with the following conditions or symptoms are excluded:
Uncontrolled diarrhea or clinically significant gastrointestinal symptoms including persistent nausea or abdominal pain.
Antimetabolites. Interferons. Other nucleoside analogs. Zidovudine (AZT). Any investigational drug.
Patients with the following are excluded:
Any concomitant conditions listed in Exclusion Co-Existing Conditions.
Karnofsky score < 70.
Hypersensitivity to acyclovir.
Displaying signs of dementia or decreased mentation which would interfere with the ability of the subject to follow protocol schedule.
Anti-cytomegalovirus therapy including ganciclovir therapy for treatment of CMV disease.